top of page

Company Announcements

ProtonDx Welcomes New CFO, Ann Wong, to Drive Scale-up and Commercial Expansion

Thu, March 16th 2023

Ann Wong brings extensive experience of scaling organisations and leading finance operations. 

Company Announcements

Dragonfly Respiratory Panel Reliably Identifies Five Most Common Causes of Respiratory Infections, Joins List of UK Approved Diagnostic Products

Mon, February 6th 2023

Rapid molecular point-of-care diagnostic system reliably detects SARS-CoV-2, Flu A, Flu B, RSV and Human Rhinovirus. Clinical test results for CTDA validation achieved 100% sensitivity and 100% specificity. UK approval follows CE-IVD mark.

Company Announcements

ProtonDx and Katalyst Announce Strategic Partnership to Distribute Dragonfly in Vitro Diagnostic

Mon, January 9th 2023

Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly System able to detect five common respiratory pathogens at once.

Company Announcements

ProtonDx Awarded £365,000 Defra and Innovate UK Grant to Develop Porcine Lung Disease Diagnostic

Fri, September 23rd 2022

Grant to develop automated, rapid point-of-need diagnostic to provide a sustainable and resilient revolution in detection and diagnosis of Porcine Respiratory Disease Complex (PRDC). Working in collaboration with Imperial College, farmers and industry experts to help address the global issue of rising antibiotic resistance.

Company Announcements

ProtonDx’s Dragonfly Diagnostic System Successfully Deployed at the 2022 Commonwealth Games

Tue, August 30th 2022

5-in-1 Respiratory Test Panel from ProtonDx used to assess elite athletes at the 2022 Commonwealth Games.

Company Announcements

New Rapid Multi-Viral Diagnostic Kit Receives CE-IVD Mark

Tue, June 21st 2022

Dragonfly™ detects SARS-CoV-2, Flu A, Flu B, RSV and human rhinovirus without a lab. It is a cost-effective point-of-need portable diagnostic system for infectious disease now commercially available.

Company Announcements

ProtonDx Tackles Malaria Diagnosis

Fri, April 29th 2022

Lacewing, the futuristic lab-on-a-chip, diagnostic tool is one of eight initiatives promoted by Imperial College London to mark Malaria Day, 25 April, in order to demonstrate the College’s deep commitment to conquering malaria. Lacewing is being developed for health care applications by Imperial spin out company ProtonDx based at the College’s Translation and Innovation HUB (I-HUB), White City Campus.

Company Announcements

Dragonfly Goes Olympic

Tue, April 26th 2022

The Dragonfly Respiratory Diagnostic Panel was utilised by the Team GB clinical staff with great success to test Great Britain's athletes at the 2022 Olympic Winter Games in Beijing.

Company Announcements

ProtonDx CEO Award for Inspiration

Mon, December 20th 2021

ProtonDx CEO, Professor Pantelis Georgiou has won an award for his inspirational work from his colleagues in the Department of Electrical and Electronic Engineering, Imperial College London

Company Announcements

Imperial Biomedical Hub Officially Opened

Mon, December 6th 2021

ProtonDx is privileged to have secured office space in the prestigious Translation and Innovation Hub (IHUB) at White City campus of Imperial College London.

Company Announcements

Best of British Recognises ProtonDx

Thu, September 23rd 2021

The work of the ProtonDx team has been recognized in Best of British a government publication produced jointly with Malaria NO MORE.

Company Announcements

ProtonDx CEO Appointed Professor of Biomedical Electronics

Wed, September 22nd 2021

CEO of ProtonDx, Dr Pantelis Georgiou, was promoted to Professor of Biomedical Electronics in the annual promotion round at Imperial College London, one of only six to achieve this accolade this year.  

bottom of page